Ioannis Stanopoulos

Ioannis Stanopoulos

Auto-generated profile, based on publicly available information

Ioannis Stanopoulos

Respiratory Failure Unit, “G. Papanikolaou” Hospital, 57010 Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
CHRISTINA ROUTSICHRISTINA ROUTSI
CHRISTINA ROUTSI
ISIoannis Stanopoulos
Ioannis Stanopoulos
SKStelios Kokkoris
Stelios Kokkoris
ASAntonios Sideris
Antonios Sideris
SZSpyros Zakynthinos
Spyros Zakynthinos
Among the multiple causes of weaning failure from mechanical ventilation, cardiovascular dysfunction is increasingly recognized as a quite frequent cause that can be treated successfully. In this review, we summarize the contemporary evidence of the most important clinical and diagnostic aspects of weaning failure of cardiovascular origin with special focus on treatment. Pathophysiological mechanisms are complex and mainly include increase in right and left ventricular preload and afterload and potentially induce myocardial ischemia. Patients at risk include those with preexisting cardiopulmonary disease either known or suspected. Clinically, cardiovascular etiology as a predominant cause or a contributor to weaning failure, though critical for early diagnosis and intervention, may be difficult to be recognized and distinguished from noncardiac causes suggesting the need of high suspicion. A cardiovascular diagnostic workup including bedside echocardiography, lung ultrasound, electrocardiogram and biomarkers of cardiovascular dysfunction or other adjunct techniques and, in selected cases, right heart catheterization and/or coronary angiography, should be obtained to confirm the diagnosis. Official clinical practice guidelines that address treatment of a confirmed weaning-induced cardiovascular dysfunction do not exist. As the etiologies of weaning-induced cardiovascular dysfunction are diverse, principles of management depend on the individual pathophysiological mechanisms, including preload optimization by fluid removal, guided by B-type natriuretic peptide measurement, nitrates administration in excessive afterload and/or myocardial ischemia, contractility improvement in severe systolic dysfunction as well as other rational treatment in specific indications in order to lead to successful weaning from mechanical ventilation.

15 November 2010 in Critical Care
Verified
Journal Article
Open access
PDF file
CRChristina Routsi
Christina Routsi
ISIoannis Stanopoulos
Ioannis Stanopoulos
Epaminondas ZakynthinosEpaminondas Zakynthinos
Epaminondas Zakynthinos
PPPanagiotis Politis
Panagiotis Politis
VPVassilios Papas
Vassilios Papas
SZSpyros Zakynthinos
Spyros Zakynthinos
Introduction: Both experimental and clinical data give convincing evidence to acute cardiac dysfunction as the origin or a cofactor of weaning failure in patients with chronic obstructive pulmonary disease. Therefore, treatment targeting the cardiovascular system might help the heart to tolerate more effectively the critical period of weaning. This study aims to assess the hemodynamic, respiratory and clinical effects of nitroglycerin infusion in difficult-to-wean patients with severe chronic obstructive pulmonary disease. Methods: Twelve difficult-to-wean (failed ≥ 3 consecutive trials) chronic obstructive pulmonary disease patients, who presented systemic arterial hypertension (systolic blood pressure ≥ 140mmHg) during weaning failure and had systemic and pulmonary artery catheters in place, participated in this prospective, interventional, non-randomized clinical trial. Patients were studied in two consecutive days, i.e., the first day without (Control day) and the second day with (Study day) nitroglycerin continuous intravenous infusion starting at the beginning of the spontaneous breathing trial, and titrated to maintain normal systolic blood pressure. Hemodynamic, oxygenation and respiratory measurements were performed on mechanical ventilation, and during a 2-hour T-piece spontaneous breathing trial. Primary endpoint was hemodynamic and respiratory effects of nitroglycerin infusion. Secondary endpoint was spontaneous breathing trial and extubation outcome. Results: Compared to mechanical ventilation, mean systemic arterial pressure, rate-pressure product, mean pulmonary arterial pressure, and pulmonary artery occlusion pressure increased [from (mean ± SD) 94 ± 14, 13708 ± 3166, 29.9 ± 4.8, and 14.8 ± 3.8 to 109 ± 20mmHg, 19856 ± 4877mmHg b/min, 41.6 ± 5.8mmHg, and 23.4 ± 7.4 mmHg, respectively], and mixed venous oxygen saturation decreased (from 75.7 ± 3.5 to 69.3 ± 7.5%) during failing trials on Control day, whereas they did not change on Study day. Venous admixture increased throughout the trial on both Control day and Study day, but this increase was lower on Study day. Whereas weaning failed in all patients on Control day, nitroglycerin administration on Study day enabled a successful spontaneous breathing trial and extubation in 92% and 88% of patients, respectively. Conclusions: In this clinical setting, nitroglycerin infusion can expedite the weaning by restoring weaning-induced cardiovascular compromise.

6 May 2012 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
GPGEORGIA PITSIOU
GEORGIA PITSIOU
VBVasilis Bagalas
Vasilis Bagalas
ABAfroditi Boutou
Afroditi Boutou
ISIoannis Stanopoulos
Ioannis Stanopoulos
PAParaskevi Argyropoulou-Pataka
Paraskevi Argyropoulou-Pataka

1 January 2018 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
MBMaria Anna Bazmpani
Maria Anna Bazmpani
Alexandra ArvanitakiAlexandra Arvanitaki
Alexandra Arvanitaki
MTMaria Toumpourleka
Maria Toumpourleka
GPGEORGIA PITSIOU
GEORGIA PITSIOU
EPEvangelia Panagiotidou
Evangelia Panagiotidou
George GiannakoulasGeorge Giannakoulas
George Giannakoulas
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, distinct pulmonary vascular disease, and therefore, there is a lack of data regarding its clinical presentation, diagnosis, and management at a national basis. We aimed to describe the demographics and management of patients with CTEPH in Northern Greece. We conducted a retrospective, observational study by a joint collaboration between two pulmonary hypertension expert centers in Greece, and the study included patients diagnosed with CTEPH. The patient population was divided into two groups depending on their operability. Overall, 27 consecutive patients were included (59% female, mean age 59.3±15.1 years). Dyspnea and fatigue were the most common presenting symptoms. History of pulmonary embolism was present in 82%. Of patients, 18 (67%) were assessed as operable, of whom 10 (55%) finally underwent pulmonary endarterectomy (PEA). There were no differences in symptoms, WHO functional class, 6-min walking test distance, and hemodynamics between the operable and nonoperable groups. At the end of follow-up, all non-operable and operable patients who did not receive surgical treatment were treated with at least one pulmonary hypertension-specific drug. This is the first report that presents data of patients diagnosed with CTEPH in Greece. The percentage of patients who underwent surgical treatment is lower but approaches the reported rates in large registries. Considering that PEA is a relatively safe and potentially curative surgical procedure, we emphasize the need for establishing a designated PEA center in Greece.

30 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EDEftychia Demerouti
Eftychia Demerouti
PKPanagiotis Karyofyllis
Panagiotis Karyofyllis
VVVassilios Voudris
Vassilios Voudris
MHMEDITERRANEO HOSPITAL
MEDITERRANEO HOSPITAL
GAGeorge Anastasiadis
George Anastasiadis
O(on behalf of the Hellenic Society for the Study of Pulmonary Hypertension (HSSPH)
on behalf of the Hellenic Society for the Study of Pulmonary Hypertension (HSSPH)
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a rare disease with poor prognosis if left untreated, characterized by pulmonary vascular bed obstruction due to unresolving thromboembolic material. The Hellenic pulmonary hypertension registry (HOPE) was launched in Greece in early 2015 and enrolls patients from all pulmonary hypertension subgroups in Greece. In total, 98 patients with CTEPH were enrolled from January 2015 until November 2019. Of these patients, 55.1% represented incident population, 50% were classified in the World Health Organization functional class II and 49% had a history of acute pulmonary embolism. The median values of pulmonary vascular resistance (PVR) and cardiac index were 7.4 (4.8) WU and 2.4 (1.0) L/min/m2, respectively, the mean diffusing capacity for carbon monoxide was 74.8 ± 20.6%, the median 6-minute walk distance was 347 (220) meters and the median value of N Terminal-pro brain natriuretic peptide was 506.0 (1450.0) pg/mL. In total, 60.2% of the patients were under pulmonary arterial hypertension-targeted therapy at the time of enrolment; specifically, riociguat was received by 35.7% of the patients and combination therapy was the preferred strategy for 16% of the patients. In total, 74 patients were evaluated for pulmonary endarterectomy (PEA), 34 (45.9%) were assessed as operable but only 23 of those (31.1%) finally underwent PEA. The remaining 40 patients were ineligible for PEA according to the operability assessment and 13 (17.6%) of them underwent balloon pulmonary angioplasty. The age of the non-operable patients was significantly higher than the operable patients (p < 0.001), while there was no significant difference with regard to the history of coagulopathies between the operable and non-operable patients (p = 0.33).

24 January 2013
Verified
Journal Article
Closed access
APAntonios Pitsis
Antonios Pitsis
TKTimotheos G Kelpis
Timotheos G Kelpis
GPGEORGIA PITSIOU
GEORGIA PITSIOU
ISIoannis Stanopoulos
Ioannis Stanopoulos
ATAlexandros Tatlis
Alexandros Tatlis
NNNikolaos E Nikoloudakis
Nikolaos E Nikoloudakis